On Nov 19, major Wall Street analysts update their ratings for $Regenxbio (RGNX.US)$, with price targets ranging from $18 to $50.
Morgan Stanley analyst Judah Frommer maintains with a buy rating, and maintains the target price at $22.
BofA Securities analyst Alec Stranahan maintains with a buy rating, and adjusts the target price from $28 to $25.
Barclays analyst Gena Wang maintains with a buy rating, and maintains the target price at $50.
Raymond James analyst Danielle Brill maintains with a buy rating, and maintains the target price at $18.
Leerink Partners analyst Mani Foroohar maintains with a buy rating, and adjusts the target price from $34 to $38.
Furthermore, according to the comprehensive report, the opinions of $Regenxbio (RGNX.US)$'s main analysts recently are as follows:
The attractiveness of gene therapy for VEGF-mediated diseases is acknowledged due to the unmet need. However, the potential limitations of subretinal delivery on commercial uptake are noted, and it's mentioned that the data on suprachoroidal delivery is still preliminary. The upcoming first functional results for RGX-202 in Duchenne muscular dystrophy will be discussed in a company webcast.
Here are the latest investment ratings and price targets for $Regenxbio (RGNX.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月19日，多家華爾街大行更新了$Regenxbio (RGNX.US)$的評級，目標價介於18美元至50美元。
摩根士丹利分析師Judah Frommer維持買入評級，維持目標價22美元。
美銀證券分析師Alec Stranahan維持買入評級，並將目標價從28美元下調至25美元。
巴克萊銀行分析師Gena Wang維持買入評級，維持目標價50美元。
瑞傑金融分析師Danielle Brill維持買入評級，維持目標價18美元。
Leerink Partners分析師Mani Foroohar維持買入評級，並將目標價從34美元上調至38美元。
此外，綜合報道，$Regenxbio (RGNX.US)$近期主要分析師觀點如下：
以下爲今日5位分析師對$Regenxbio (RGNX.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
